Inotrem
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
54 Rue De Ponthieu, Paris, Ile-de-France...Phone Number
+33 966817900Website
www.inotrem.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Inotrem
Inotrem is a biotechnology company focused on developing innovative immunomodulatory therapies that target the TREM-1 pathway to restore balance in life-threatening inflammatory conditions. Their lead product, INO-01 (nangibotide), is a first-in-class peptidic TREM-1 inhibitor aimed at treating septic shock and severe COVID-19, with proven clinical efficacy. The company also offers a companion diagnostic tool developed in partnership with Roche Diagnostics to identify patients who would benefit from their therapies. Inotrem's solutions are designed for patients suffering from acute inflammatory syndromes driven by dysregulated immune responses.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inotrem your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Inotrem has new funding data
Congratulate Masked Content for being promoted to Masked Content at Inotrem
Website visits: Recent activity has been detected on your website
Check if Inotrem has recently received funding, and reach out quickly before it becomes old news!
Inotrem, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Inotrem recently announced quarterly report
Check out if Inotrem is spiking on competitors!
Product Launch: Get notified when Inotrem launches new products
Click to see if Inotrem had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Inotrem
Find 2 more new buyers
Company Profile Activity
Activity Insights
Inotrem is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inotrem is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inotrem.
Inotrem financials insights
Gather financial insights about Inotrem, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$21.8M
2020
Series B
$63.7M
Inotrem Tech Stack
A closer look at the technologies used by Inotrem
See more technologies
Most Recent Scoops
Funding
New Hire
Executive Move
Lateral Move
Executive Move
Lateral Move
Executive Move
New Hire
Executive Move
Inotrem News & Media
Inotrem Receives Milestone Funding From the Crohn’s & Colitis Foundation IBD Ventures Program to Advance Its Inflammatory Bowel Disease Pipeline
PARIS--(BUSINESS WIRE)-- #biotech--Inotrem receives milestone funding from the Crohn’s & Colitis Foundation following the review of its antibody program interim data.Inotrem Announces Publication of Two Key Articles on Nangibotide Phase II Programs in Peer-reviewed Medical Journals
PARIS--(BUSINESS WIRE)-- #PIA--Inotrem publishes two key articles on nangibotide Phase 2 programs in The Lancet Respiratory Medicine and eClinicalMedicine.Inotrem Receives Funding From the Crohn’s & Colitis Foundation to Help Develop New Therapeutic Approaches in Inflammatory Bowel Disease (IBD)
PARIS--(BUSINESS WIRE)-- #IBD--Inotrem Receives Funding from the Crohn’s & Colitis Foundation to Help Develop a New Therapeutic Approach in IBD Focusing on the TREM-1 PathwayInotrem Announces That Its ESSENTIAL Phase II Study for the Treatment of Critically ill COVID-19 Patients Meets Its Primary and Key Secondary Endpoints
PARIS--(BUSINESS WIRE)-- #biotech--Inotrem's ESSENTIAL Phase II study for the treatment of critically ill COVID-19 patients meets primary and key secondary endpoints.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inotrem
Sign Up For FreeTo access detailed company insights
Inotrem is a biotechnology company focused on developing innovative immunomodulatory therapies that target the TREM-1 pathway to restore balance in life-threatening inflammatory conditions. Their lead product, INO-01 (nangibotide), is a first-in-class peptidic TREM-1 inhibitor aimed at treating septic shock and severe COVID-19, with proven clinical... Read More
